Soignies, Belgium

Larurent Provins

USPTO Granted Patents = 1 

Average Co-Inventor Count = 16.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Inventor Laurent Provins: Innovating in CNS Treatments**

Introduction

Laurent Provins, an accomplished inventor based in Soignies, Belgium, has made significant contributions to the field of pharmaceutical sciences. His work focuses on developing innovative compounds that can modulate certain receptors, paving the way for potential treatments of various central nervous system (CNS) diseases.

Latest Patents

Laurent Provins holds a patent for "Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides." This invention discloses a series of sulfonamide compounds characterized by their ability to modulate GPR17 properties. These compounds hold promise for treating and preventing a range of CNS diseases, particularly myelinating disorders, thereby contributing to advancements in neuropharmacology.

Career Highlights

Throughout his career, Laurent has been associated with UCB Pharma GmbH, a well-respected pharmaceutical company known for its innovative approaches to serious diseases. His role there underscores his commitment to research and development in the field of therapeutic compounds.

Collaborations

Laurent Provins has effectively collaborated with several talented professionals in his field, including Christa E Mueller and Cécile Pegurier. These partnerships facilitate a creative and productive environment that often leads to groundbreaking discoveries and advancements in drug development.

Conclusion

In summary, Laurent Provins is a noteworthy inventor whose contributions through his patent and collaborations at UCB Pharma GmbH play a vital role in the ongoing fight against CNS diseases. His innovative spirit and dedication to research continue to inspire peers and future generations in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…